Activated vinylcyclopropanes (VCPs) can form zwitterionic π-allylmetal species in the presence of transition metals and are widely used in organic synthesis. A nickel-catalyzed asymmetric allylation of secondary phosphine oxide with...
Nickel demonstrates excellent performance in C-C or C-X cross-coupling reactions involving a SET process. However, the Ni(I)/Ni(III) two-electron pathway, which does not require light irradiation, is still rare, particularly in the asym-metric version. Here, we disclose a Ni(II)-catalyzed asymmetric C-P cross-coupling reaction via the Ni(I)/Ni(III) two-electron redox pathway. Combined experimental and computational research reveals that Ni(II) can be readily reduced to Ni(0) by secondary phosphine oxides, resulting in the formation of a Ni(I) active catalyst through comproportiona-tion. The discovery of the Ni(I)/Ni(III) two-electron mechanism may serve as a new paradigm of Ni catalysis, offering exciting opportunities in asymmetric reactions complementary to the traditional SET process.
An asymmetric arylation of H-phosphinates with aromatic iodo or bromo compounds, catalyzed by cheap and easily available nickel(II) salts, provides access to P-stereogenic phosphinates. This method features mild reaction conditions and a good functional-group compatibility that includes aniline and phenol derivatives.
Nickel
performs excellently in C–C and C–X cross-coupling
reactions. Here, we disclose a Ni(II)-catalyzed asymmetric C–P
cross-coupling reaction to afford valuable chiral heterocyclic tertiary
phosphine oxides. The method is mild and efficient, which invokes
a self-sustained nickel catalytic cycle without an external reductant,
light irradiation, or electricity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.